Jan 21 2010
Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. District Court for the District of Delaware has found all four patents in a suit involving Johnson & Johnson to be invalid.
As part of a 2007 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings (drug and polymer) for drug-eluting stents.
The Court ruled today that a trial on the four patents, which was scheduled to begin February 9, will not proceed.
"We are pleased with the Court's finding that all four Johnson & Johnson patents are invalid," said Ray Elliott, President and Chief Executive Officer of Boston Scientific. "Boston Scientific will continue to vigorously defend against any charges of infringement. We continue to attempt to resolve remaining outstanding matters with Johnson & Johnson."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
SOURCE Boston Scientific Corporation